BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 10438708)

  • 1. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.
    Dördelmann M; Reiter A; Borkhardt A; Ludwig WD; Götz N; Viehmann S; Gadner H; Riehm H; Schrappe M
    Blood; 1999 Aug; 94(4):1209-17. PubMed ID: 10438708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.
    Schrappe M; Aricò M; Harbott J; Biondi A; Zimmermann M; Conter V; Reiter A; Valsecchi MG; Gadner H; Basso G; Bartram CR; Lampert F; Riehm H; Masera G
    Blood; 1998 Oct; 92(8):2730-41. PubMed ID: 9763557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone.
    Felice MS; Zubizarreta PA; Alfaro EM; Sackmann-Muriel F
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):411-5. PubMed ID: 11878573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome of patients with childhood acute lymphoblastic leukaemia and an initial leukaemic blood blast count of less than 1000 per microliter.
    Lauten M; Stanulla M; Zimmermann M; Welte K; Riehm H; Schrappe M
    Klin Padiatr; 2001; 213(4):169-74. PubMed ID: 11528550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.
    Conter V; Schrappe M; Aricó M; Reiter A; Rizzari C; Dördelmann M; Valsecchi MG; Zimmermann M; Ludwig WD; Basso G; Masera G; Riehm H
    J Clin Oncol; 1997 Aug; 15(8):2786-91. PubMed ID: 9256120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
    Möricke A; Zimmermann M; Valsecchi MG; Stanulla M; Biondi A; Mann G; Locatelli F; Cazzaniga G; Niggli F; Aricò M; Bartram CR; Attarbaschi A; Silvestri D; Beier R; Basso G; Ratei R; Kulozik AE; Lo Nigro L; Kremens B; Greiner J; Parasole R; Harbott J; Caruso R; von Stackelberg A; Barisone E; Rössig C; Conter V; Schrappe M
    Blood; 2016 Apr; 127(17):2101-12. PubMed ID: 26888258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.
    Reiter A; Schrappe M; Ludwig WD; Hiddemann W; Sauter S; Henze G; Zimmermann M; Lampert F; Havers W; Niethammer D
    Blood; 1994 Nov; 84(9):3122-33. PubMed ID: 7949185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.
    Aricò M; Valsecchi MG; Conter V; Rizzari C; Pession A; Messina C; Barisone E; Poggi V; De Rossi G; Locatelli F; Micalizzi MC; Basso G; Masera G
    Blood; 2002 Jul; 100(2):420-6. PubMed ID: 12091331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
    Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
    J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of therapy results and prognostic factors in children with acute lymphoblastic leukaemia in Warmia and Mazury region: 17-years experience].
    Badowska W
    Med Wieku Rozwoj; 2008; 12(4 Pt 2):1001-7. PubMed ID: 19531816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.
    Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G
    J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
    Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
    Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
    Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of glucocorticoid induction test in Chinese childhood acute lymphoblastic leukemia].
    Fan JJ; Chai YH; Hu SY; He HL; Zhao WL; Wang Y; Li J; Lu J; Xiao PF; Sun YN; Wang W; Cao L
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):523-6. PubMed ID: 24267134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.
    Steinherz PG; Gaynon PS; Breneman JC; Cherlow JM; Grossman NJ; Kersey JH; Johnstone HS; Sather HN; Trigg ME; Chappell R; Hammond D; Bleyer WA
    J Clin Oncol; 1996 Feb; 14(2):389-98. PubMed ID: 8636748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
    Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
    Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.